Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Assets (2023 - 2025)

CG Oncology (CGON) has disclosed Non-Current Assets for 3 consecutive years, with $32.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 5371.38% year-over-year to $32.1 million, compared with a TTM value of $121.6 million through Dec 2025, up 6163.85%, and an annual FY2025 reading of $32.1 million, up 5371.38% over the prior year.
  • Non-Current Assets was $32.1 million for Q4 2025 at CG Oncology, down from $34.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $34.1 million in Q3 2025 and bottomed at $391000.0 in Q3 2024.
  • Average Non-Current Assets over 3 years is $14.3 million, with a median of $5.2 million recorded in 2023.
  • The sharpest move saw Non-Current Assets crashed 88.66% in 2024, then surged 8627.11% in 2025.
  • Year by year, Non-Current Assets stood at $5.2 million in 2023, then plummeted by 88.66% to $587000.0 in 2024, then surged by 5371.38% to $32.1 million in 2025.
  • Business Quant data shows Non-Current Assets for CGON at $32.1 million in Q4 2025, $34.1 million in Q3 2025, and $28.4 million in Q2 2025.